Accumulated Treatment Cost of New Therapies in Multiple Myeloma- Comparing the Combination of Daratumumab, Bortezomib and Dexamethasone with Carfilzomib and Dexamethasone For WHO Have Received at Least One Prior Therapy in Brazil
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.2583
https://www.valueinhealthjournal.com/article/S1098-3015(17)32917-0/fulltext
Title :
Accumulated Treatment Cost of New Therapies in Multiple Myeloma- Comparing the Combination of Daratumumab, Bortezomib and Dexamethasone with Carfilzomib and Dexamethasone For WHO Have Received at Least One Prior Therapy in Brazil
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)32917-0&doi=10.1016/j.jval.2017.08.2583
First page :
A876
Section Title :
SELECTED HEALTH CARE TREATMENT STUDIES -MEDICAL DEVICE/DIAGNOSTICS
Open access? :
No
Section Order :
2384